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Economic Evaluation pf Antibacterial Usage in Ear, Nose 
and Throat Infections in a Nigerian Teaching Hospital 
Abstract 
 
Purpose: To carry out economic evaluation of antibacterial usage for 
Ear, Nose and Throat infections in a tertiary health care facility in 
Nigeria. 
Methods: Antibacterial utilisation evaluation was carried out 
retrospectively over one year period by reviewing 122 case notes 
containing 182 prescriptions of patient with Ear Nose and Throat 
infections.   Relevant data including demographics, diagnosis, 
prescribed drugs, dosages, were extracted and the associated costs 
analysed.   
Results: Highest prevalent rate of Ear, Nose and Throat infections 
occurred in children under 10 years of age (59.3%) with otitis media 
predominating (45.0%). Average antibacterial cost per case was 
N1971.37 (US$15.16).  Penicillins were the most frequently 
prescribed (35.5%) at a cost of N89,468.00 (US$688.22) representing 
24.9% of the total antibacterial cost.  Cephalosporins were used at a 
rate of 12.1% with a percentage total antibacterial cost of 48.4% 
(N173,554.00, US$1335.03).  
Conclusion:  The average cost of antibacterial agents to patients 
studied is high. This call for prudent use of these agents which should 
be evidence based and closely monitored. 
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Drug utilization review is one of the conceptual 
models for effective use of drugs [1], particularly 
if cost evaluation is included. In most developing 
countries, regulatory capacity is very weak, most 
laboratories are poorly equipped and researches 
are poorly funded. Institutionally organized drug 
utilization evaluation does not exist in most 
hospitals as well. In most of these countries, 
important data on antibacterial usage for sound 
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 “Community-acquired respiratory tract infections 
(RTIs) including bacterial sinusitis, acute otitis 
media, acute exacerbations of chronic bronchitis 
and community acquired pneumonia (CAP) are 
among the most frequent infections treated by 
physicians and represent a major international 
health problem” [2]. It has been reported that 
about 10% of the worldwide burden of morbidity 
and mortality relates to RTIs [3]. Whilst the 
majority of this is viral in aetiology, three quarter 
of all antibiotic consumption is for RTIs [3].  
Ongoing threat of antibacterial resistance coupled 
with irrational use by the public and some health 
care professionals and poor surveillance activities 
in most developing countries are indeed 
compelling reasons for concern.  
 
Infectious diseases have the greatest impact on 
human being because of their externality. Non 
affordability of quality therapy by infected 
patients has serious implications on the health 
and wealth of the nation. Delay or non-treatment 
leads to complications, increase cost, increase 
morbidity and mortality and spread due to 
communicable nature. Inadequate or 
inappropriate treatment equally leads to 
development of resistance in addition. World 
Health Organization (WHO) in 2006 also pointed 
out that one-third of the global population has no 
access to good quality Medicines [5]. Therefore, 
any useful intervention that can encourage 
accessibility and affordability will go along way 
particularly in poor countries like Sub-Sahara 
Africa where dropping out of therapy due to cost 
has been reported [4].  
 
In today’s competitive, limited-resource 
healthcare environment, choices and trade offs in 
providing healthcare services are inevitable. In 
developing countries, the cost of healthcare is 
prohibitive and borne mostly from out of pocket 
expenses. Economic evaluation is increasingly 
being advocated even in developed countries 
[6,7], but this is inadequately so in Nigeria 
among other African countries where available 
resources for healthcare are much more limited. 
Previously, emphasis has been basically on 
clinical outcomes of therapy with little critical 
consideration for economic and psychosocial 
outcomes [8,9]. Evidence-based cost related 
studies are very rare in Nigeria and among other 
developing countries for accurate health budget 
planning and reliable policy making the studies 
imperative.  The objective of the study was to 
carry out economic evaluation of antibacterial 
usage for Ear, Nose and Throat infections in the 






The study was carried out in the 764-bed Lagos 
University Teaching Hospital (LUTH), Nigeria 
which is a tertiary health care centre. The hospital 
comprises Accident and Emergency Unit as well 
as In-patient and General Out-Patient units 
including Ear, Nose and Throat (ENT) clinic. 
Total patient turnover in the hospital is about 
10,000 monthly. Various specialties and wards as 
well as diagnostic facilities, typical of teaching 
hospitals, are in place. Antibacterial agents, if 
indicated, are prescribed in all the departments 
for surgical and medical cases. The personnel 
involved are as typical of any teaching hospital 
comprising the consultants, resident doctors, 
pharmacists, medical laboratory scientists among 
others. Each of the hospital department has a 
pharmacy unit attached.   
 
Study design    
 
This was a retrospective drug utilization 
evaluation involving the use of randomly selected 
525 out-patient case notes for three categories of 
disease conditions that has antibacterial agents as 
the mainstay of therapy. This sample exceeded 
the calculated 384 case notes using standard 
statistical procedure. The period covered the year 
2005 to 2006. Out of the randomly selected case 
notes, the entire 122 containing 182 prescriptions 
for Ear, Nose and Throat Infections were 
examined. The systematic randomised sampling 
was facilitated with the aid of diagnostic coding 
cards. All age groups of relevant out-patients with 
antibiotic prescription(s) were included in the 
study. 
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Data collection  
 
Relevant data such as date of visit, demographics, 
diagnosis, type of diagnostic test, prescribed 
drugs, and dosages, frequency of dosing and 
duration of therapy were extracted using an 
appropriately designed and validated data 
collection forms. Follow-up visit if any, and test 
of cure (a repeat diagnostic test within a month of 
therapy to ascertain complete eradication of 




The surrogate clinical outcome measure 
determined included hospital visits, type of 
diagnostic tests and respective proportion of 
patients involved, test of cure and isolated 
organisms. Others were volume (in doses), type 
and class of antibacterial agents prescribed and 
appropria-teness. Also considered was whether 
the prescription was in generic or branded names.  
Economic outcomes included the cost per defined 
daily dosage of each agents (C/DDD) [10], 
antibacterial cost per visit for each patient and 
cost of each class of antibacterial agent. Others 
were average cost per dose of antibacterial agent, 
average cost of antibacterial agents per patient. 
There was no adjustment for discounting and 
inflation in cost determination as all the costs 
occurred within one year of data collection. 
However, the exchange rate of the local currency 
(naira, N) to the US dollar (US$) at the time of 
analysis was used to allow for consistency.     
Data Analysis 
 
The collected data were analysed using Epi Info 
(CDC, 2002).  Mean cost per defined daily dose 
(C/DDD) and the total cost of antibacterial agents 
per visit for each patient were computed for each 
drugs. Defined daily dose has been recommended 
for cost analysis of drugs [10]. Also determined 
were the proportions of prescriptions in generic 
and branded names, the cost for each class of 
antibacterial agents, and number of visits. The 
volume of usage in doses for each drug and 
respective class of antibacterial agents were also 
computed. Proportional data were analysed using 
chi square test and Fisher’s exact test (for small 
numbers) while mean costs were compared using 
Student T test. Descriptive statistics (means and 
percentages) were used in the presentation of 
results.  At 95% confidence interval, a 2-tailed p-




Demographic Data and Hospital Visit 
 
Disease occurrence was significantly higher 
among children of age group 0-10 years (59.3%) 
when compared to any other age group (p<0.05).  
There was no significant difference between male 
(57.7%) and female (42.3%) patients (p<0.05). 
Follow-up visits to the hospital by patients 
(33.0%) was significantly lower than first visits 
(67.0%)  by patients (p<0.05)  (Tables 1 and 2). 
                                            Table 1: Demographic data and hospital visit among ENTI patients 
 











0-10 66 (36.2) 42 (23.1) 65(35.7) 43 (23.6) 108(59.3) 
11-20 4 (2.2) 5 (2.8) 8 (4.4) 1 (0.5) 9 (4.9) 
21-30 9 (4.9) 13 (7.1) 20 (10.9) 2 (1.1) 22 (12.1) 
31-40 15 (8.2) 5 (2.8) 18 (9.9) 2 (1.1) 20 (10.9) 
41-50 2(1.1) 3 (1.6) 5 (2.7) 0 (0.0) 5 (2.7) 
51-60 3 (1.6) 9 (4.9) 4 (2.2) 8 (4.4) 12 (6.6) 
>60 6 (3.3) 0 (0.0) 2 (1.1) 4 (2.2) 6 (3.3) 
Total 105 (57.7) 77 (42.3) 122 (67.0) 60 (33.0) 182 (100.0) 
ENTIs = Ear, Nose and Throat  Infections 
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0-10 22 (12.1) 15(8.2) 65 (35.7) 3 (1.6) 3 (1.6) 108(59.3) 
11-20 5(2.8) 2 (1.1) 1 (0.5) 0 (0.0) 1 (0.5) 9(5.0) 
21-30 8(4.4) 4 (2.2) 0(0.0) 6 (3.3) 4 (2.2) 22 (12.1) 
31-40 3 (1.6) 6 (3.3) 0(0.0) 3 (1.6) 8 (4.4) 20 (10.9) 
41-50 1(0.5) 1 (0.5) 1 (0.5) 0 (0.0) 2 (1.1) 5 (2.7) 
51-60 1 (0.5) 9 (5.0) 2 (1.1) 0 (0.0) 0 (0.0) 12 (6.6) 
>60 5 (2.7) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 6 (3.3) 
Total 45 (24.7) 37 (20.3) 70 (38.5) 12 (6.6) 18 (9.9) 182 (100.0) 




Otitis media was the most prevalent and occurred 
among 82 (45.0%) patients.  Acute and chronic 
suppurative otitis media occurred in 45 (24.7%) 
and 37 (20.3%) of  the patients respectively. This 
was followed by bronchopneumonia which 
occurred among 70 (38.5%) patients.  Treatments 
were largely empirical and there were 
documented cases of microscopy culture and 
sensitivity (m/c/s) test in 14 (7.7%) patients.   
 
Drug indicator variables 
 
The total number of drugs prescribed in generic 
names were 95 (34.1%) which is significantly 
lower than those prescribed in brand names 180 
(65.9%) (p<0.05). Average number of drugs per 
prescription was 1.5 and the volume of 
antibacterial agent prescribed in doses was 5571 
doses. Penicillins, the most frequently prescribed 
shares 35.5% of the total prescriptions (Table 3). 
 
Cost variables  
 
The total antibacterial cost was N358,760.00 
(US$2759.92) with an average cost per case of 
N1971.37 (US$15.16) and average cost per dose 
of N64.40 (US$0.49). Penicillins shares 
N89,468.00 (US$688.22) representing 24.9% of 
the total antibacterial cost. Cephalosporins which 
were prescribed in 12.1% of the cases had the 
largest antibacterial share cost of N173,554.00 
(US$1335.03), with a  cost proportion of 48.4%. 
Average antibacterial cost for otitis media was 
N825.00(US$6.35) while that of broncho-
pneumonia was N3675.41±1207.58 (US$28.27 
±9.28) (Table 4). 
 
Table 3: Volume of usage of antibacterial agent in 















Penicillins  73 (26.7) 24 (8.8) 2416 (43.4) 
Cephalosporins 13 (4.8) 20 (7.3) 430 (7.7) 
Macrolides 16 (5.9) 12 (4.4) 692 (12.4) 
Quinolones 7(2.6) 5 (1.8) 150 (2.7) 
Aminoglycosides 8 (2.9) 7(2.6  ) 207 (3.7) 
Sulphonamides 5 (1.8) 6 (2.2) 128 (2.3) 
Imidazoles 20 (7.3) 13 (4.8) 693 (12.4) 
Others 30 (10.9) 14 (5.1) 855 (15.3) 
Total 172 (63.1) 101 (36.9) 5571 (100.0) 




Otitis media which was the most prevalent in 
almost half of the patient, has been previously 
reported as the commonest Ear, Nose and Throat 
infection with a prevalence rate of 14.7% in 
children 0-12 years and 29.0% in children 0-5 
years of age in South-Western Nigeria [11]. With 
a population of about 140 million [12], 29.0% in 
children below 5 years (who normally constitute 
20.0% of total population) implies about 7.7 
million cases in Nigeria. Majority of the affected 
children usually belong to low socio economic 
group who can hardly afford basic health care as 
a result of an association between infections, poor 
sanitary conditions and low standard of living.  
Most Nigerians (70.2%) have been reported to be 
living below the poverty line earning less than 
US$1 per day even before global economic      
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Table 4: Antibacterial utilization in the treatment of Ear, Nose and Throat infections 
 
Drug Class Drug 
Prescription 
Frequency  
      N (%) 
Total Drug Cost 
 N ($US) 
 
Percentage Drug Cost 
(%) 
Quinolones Ciprofloxacin 8 (2.9) 4, 468.00 (34.40) 1.2 
 Others 4  (1.5) 12,498.00(96.14) 3.4 
 Sub Total 12(4.4) 16,888.00 (129.90) 4.6 
Penicillins Cloxacillin 2 (0.7) 900.00 (6.92) 0.3 
 Coamoxiclav 33 (12.1) 61, 096.00(469.97) 17.0 
 Amoxicillin 32 (11.7) 9,278.00 (71.37 ) 2.6 
 Ampicillin 7 (2.6) 2,464.00 (18.95) 0.7 
 Ampiclox 23 (8.4) 15,730.00 (121.00) 4.4 
 Sub-Total 97 (35.5) 89,468.00 (688.20) 24.9 
Cephalosporins Ceftriaxone                   2(0.7) 12,864.00 (989.72) 24.9 
 Cefuroxime 28(10.3) 59,820.00 (460.15) 16.7 
  Ceftazidime 3 (1.1) 100, 870.00 (775.92) 28.1 
 Sub Total 33 (12.1) 173,554 (1335.03 ) 48.4 
Macrolides Erythromycin 27 (9.9) 10,852.00  (83.47) 3.0 
 Roxiithromycin 1(0.4) 650.00 (5.0) 0.2 
 Sub Total 28 (10.3) 11,502 .00 (88.48) 3.0 
Aminoglycosides Gentamicin 14 (5.1) 5,240.00 (40.31) 1.4 
 Amikacin 1 (0.4) 43,820.00 (337.08) 12.2 
 Sub-Total 15 (5.5) 49,060.00 (377.38) 13.7 
Sulphonamides Co-trimoxazole 11 (4.0) 2,152.00 (16.55) 0.6 
Imidazoles Metronidazole 33(12.1) 3,636.00 (27.97) 1.0 
Others Ear Drops 44 (16.1) 12,530.00 (96.38) 3.5 
 Grand Total 273 (100.0) 358,790.00 (2759.92) 100.0 
Exchange rate at the time of the study: $1=130;  No adjustment for inflation or discounting was carried out 
 
meltdown12 indicating poor affordability of 
quality health care services. 
 
Average antibacterial cost from the study for 
treating otitis media was N825.00 (US$6.35) 
{N542±62.00 SEM (US$4.17±0.48) for acute and 
N1161.68±221.4 SEM (US$8.93±1.7) for chronic 
suppurative}. This gives about N6.35 billion 
(US$48.87 million) as antibacterial cost alone for 
an estimated 7.7 million cases of otitis media in 
Nigeria. Average antibacterial cost of 
N3675.41±1207.58(US$28.27±9.28) for broncho-
pneumonia is also prohibitive. Overall average 
antibacterial cost per case of N1971.37 
(US$15.16) is very high. Poor patients can hardly 
afford this, complications and spread of the 
infections occurs particularly in crowded settings 
of low socio economic group. Free health care 
from government is strongly advocated for 
children below 12 years. Education of patients 
and care givers on personal hygiene, 
environmental sanitation is also necessary.  There 
should be enhanced capacity building and facility 
provision to promote rapid diagnosis. Provision 
of regularly up-dated evidence-based treatment 
guidelines, data base on antibacterial resistance 
and sustainable surveillance activities, to guide 
empiric therapy are also necessary.  
   
The antibacterial agents were rationally 
prescribed but largely empirical. Antibacterial 
susceptibility testing in seven percent of cases 
reviewed is very low. Empirical antibacterial 
therapy is a major factor in the development of 
antibacterial resistance [13,14]. However, empiric 
therapy is somewhat inevitable in Nigeria due to 
poor diagnostic facilities and poverty among 
many patients who may not be able to afford 
quality health care services. Over the counter 
prescription of antibacterial agents even by 
quacks, in effective drug distribution system, 
weak regulations and poor surveillance activities 
are other factors seriously threatening 
antibacterial therapy success in Nigeria and other 
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developing countries. It is important to address 
these by all the stakeholders urgently.  
   
More than two-third of prescriptions were in 
branded names instead of generic (p<0.05) in 
contrary to recommendations of National Drug 
Policy of 2005[15].  Lack of adequate awareness 
on the implications may be responsible. It makes 
patients to think that generic products are 
inferior; hence societies including poor teaming 
masses are tactically being forced to spend more 
in buying the branded products. However, lack of 
trust as regard the quality of some generic 
products might be a factor. Generic prescription 
should be encouraged particularly for developing 
countries where health spending per capita is 
about US$15.00 - US$21.00 annually, unlike 
developed countries where per capita health 
spending is about US$2000.00[16]. Quality 
control of generics should be strengthened and 
evidence of efficacy ascertained periodically.  
      
The most widely prescribed class of drug was the 
penicillins at a frequency of 35%, at a cost of 
N89,468.00 (US$688.22) representing 24.9% of 
total antibacterial cost for all agents. This 
observation is in agreement with previous reports 
[17]. Cephalosporins were second to the 
penicillins at a prescribing rate of 12.1% but with 
a whopping cost of N173,554 (US$1335.03) 
which represents about half of the total 
antibacterial cost.  Out of the 12.1%, cefuroxime 
alone constitutes 10.1% but only 16.7% of the 
huge cost. This is probably because of its 
availability in oral formulations in addition to 
injection.   
 
The cost proportions of co-amoxiclav among the 
penicillins and other cephlosporins apart from 
cefuroxime indicates that usually few drugs are 
responsible for high total cost of antibacterial 
therapy. Their usage should be monitored and 
cost effectiveness analysis carried out on regular 
basis to monitor their use and optimise therapy.  
Conclusion 
Antibacterial cost to patients and by extension the 
nation at large is enormous and a greater 
proportion of the antibacterial cost is due to few 
agents. This call for prudent use of these agents 
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